Selexipag Drug Asset Due Diligence Report 2026

This Selexipag Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Selexipag can convert its Small molecule drug profile and PGI2 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Selexipag (query alias: selexipag)
Modality / target	Small molecule drug; PGI2 receptor; PGI2 receptor agonists
Highest global status	Approved
Originator	Nippon Shinyaku Co., Ltd.
Active developers	Janssen Pharmaceutica NV, Janssen, Inc., Actelion Pharmaceuticals Ltd.

The MCP disease footprint includes Chronic thromboembolic pulmonary hypertension, Pulmonary Arterial Hypertension, Idiopathic pulmonary arterial hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2071250134	Phase 3	募集中	194	対数変換した最大歩行時間のベースラインからの変化量
JPRN-jRCT2071250135	Phase 3	募集中	50	Safety of Long-Term Administration (52 weeks) of NS-304
NCT07694128	Phase 1	Completed	30	Maximum concentration obtained (Cmax)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

REAL-LIFE EFFECTIVENESS OF SELEXIPAG TREATMENT IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: LONG-TERM DATA FROM A MULTICENTRIC ITALIAN COHORT

Not Applicable; n=51; evaluation: Positive. Reported fields: 6MWD = 293.0 m ( 180 - 380)

A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension

Phase 2; n=63; evaluation: Positive. Reported fields: AE = 62.0 Pts

Real-world Retrospective Cohort Study of Oral Selexipag in Methamphetamine-associated Pulmonary Arterial Hypertension: An Interim Analysis From TEAM PAH

Not Applicable; n=67; evaluation: not stated. Reported fields: Individualized dose = 800 µg BID

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Selexipag addresses Chronic thromboembolic pulmonary hypertension, Pulmonary Arterial Hypertension, Idiopathic pulmonary arterial hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2017-12-21	Handok to sell Actelion’s hypertension drug Uptravi	Approved	Financial terms not disclosed
2008-04-21	Actelion and Nippon Shinyaku enter into a license agreement on novel PAH compound	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “A tablet formulation comprising selexipag”. The milestone feed surfaced a patent-application signal described as “A film coated tablet comprising selexİPAG processed with wet granulation”. The milestone feed surfaced a patent-application signal described as “A film coated tablet comprising selexİPAG and its preparation process”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO